Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Target Price at $17.75

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $17.75.

ATRA has been the topic of several research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $17.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, March 11th. RODMAN&RENSHAW lowered Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target for the company. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th.

Atara Biotherapeutics Stock Performance

NASDAQ ATRA opened at $6.53 on Friday. The firm has a market capitalization of $38.26 million, a price-to-earnings ratio of -0.25 and a beta of 0.49. Atara Biotherapeutics has a one year low of $5.40 and a one year high of $20.81. The company’s 50 day moving average price is $7.59 and its 200 day moving average price is $9.62.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.82) by $2.63. The business had revenue of $32.75 million during the quarter, compared to analyst estimates of $20.58 million. Sell-side analysts forecast that Atara Biotherapeutics will post -10.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics during the 4th quarter worth approximately $48,000. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics in the fourth quarter worth $169,000. Citadel Advisors LLC raised its holdings in Atara Biotherapeutics by 2.6% in the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock valued at $3,558,000 after acquiring an additional 6,873 shares in the last quarter. Bank of America Corp DE boosted its stake in Atara Biotherapeutics by 0.8% during the 4th quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock valued at $2,731,000 after acquiring an additional 1,543 shares during the last quarter. Finally, Northern Trust Corp acquired a new position in Atara Biotherapeutics during the 4th quarter worth $149,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.